Considerations in Our Search for Interferons for Clinical Use

Abstract

Interferon has yet to become the drug of choice for any clinical disease entity, but several promising uses are being pursued. Clinical trials are limited probably because interferon is so expensive. Cheaper interferon would probably stimulate more clinical trials. Demonstrated efficacy in a disease of considerable magnitude would spur the search for cheaper interferon. Possible ways to look for more, cheaper interferon are suggested. The need to understand the chemical and structural composition of interferon is pointed out especially the role played by carbohydrates. There is a need for a non- biological, yet sensitive quantitative measurement of interferon; development of an immune assay is suggested. The need to restudy ways to apply interferon to target tissues and the need for a standardized product for use in clinical trials are pointed out.